April 22, 2014

Helix BioPharma Corp. Receives U.S. FDA Approval to Initiate a Clinical Trial of L-DOS47 (PDF)

Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company
developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received approval from the U.S. Food and Drug Administration (“FDA”), to initiate a Phase I clinical trial with L-DOS47.